Format

Send to

Choose Destination
Bull Cancer. 2015 Apr;102(4):324-31. doi: 10.1016/j.bulcan.2014.08.001. Epub 2015 Mar 3.

Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.

Author information

1
Hôpital Saint-Antoine, 75012 Paris, France.
2
Hôpital Henri-Mondor, 94000 Créteil, France.
3
Hôpital européen George-Pompidou, 75015 Paris, France.
4
Institut mutualiste Montsouris, 75014 Paris, France.
5
Hôpital de la Pitié-Salpêtrière, 75013 Paris, France.
6
Hôpital Beaujon, 92110 Clichy, France.
7
Institut régional du cancer Montpellier - Val-d'Aurelle, 34000 Montpellier, France.
8
Institut hospitalier franco-britannique, 92300 Levallois-Perret, France; GERCOR-IRC (Groupe coopérateur multidisciplinaire en oncologie-Innovative Research Consortium), 151, rue du Faubourg-Saint-Antoine, 75011 Paris, France.
9
Institut hospitalier franco-britannique, 92300 Levallois-Perret, France.
10
Hôpital Saint-Antoine, 75012 Paris, France. Electronic address: thierry.andre@sat.aphp.fr.

Abstract

BACKGROUND:

Trastuzumab with 5-fluorouracil (5-FU) and cisplatin offers prolonged survival in patients with HER2-overexpressing advanced gastric cancer (AGC) and advanced gastro-oesophageal junction cancer (AGOJ). Oxaliplatin in combination with intravenous 5-FU plus leucovorin (LV; modified [m]FOLFOX6) or capecitabine (XELOX) improves tolerability compared with 5-FU/cisplatin regimen. There are few data available on the efficacy and safety of trastuzumab-oxaliplatin-based chemotherapy in previously untreated HER2-positive AGC and AGOJ patients.

METHODS:

Clinical data were retrospectively analysed in patients receiving trastuzumab plus mFOLFOX6 or XELOX as first-line therapy between July 2009 and December 2012. Eligible patients had histologically proven AGC or AGOJ, HER2 overexpression, and no prior chemotherapy for metastatic disease.

RESULTS:

Thirty-four patients met the eligibility criteria. Median age was 63 years, 79% of patients had ECOG PS score of 0-1, and all had metastatic disease. Median duration of treatment was 7.5 months. Overall response rate was 41% (95% CI: 25-56). Median progression-free survival and overall survival were 9.0 months (95% CI: 5.6-12) and 17.3 months (95% CI: 13.5-32.3), respectively. Tolerability was acceptable. The most frequent grade 3-4 toxicities were neutropenia (8.8%) and neuropathy (17.6%).

CONCLUSION:

mFOLFOX6-trastuzumab combination is an efficient regimen with an acceptable safety profile for AGC and AGOJ patients. These results warrant further prospective study.

KEYWORDS:

Cancer gastrique; Oxaliplatin; Oxaliplatine; Stomach neoplasms; Trastuzumab

PMID:
25744576
DOI:
10.1016/j.bulcan.2014.08.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center